Is ibogaine legal in the United States? (Updated for the 2026 executive order)

Ibogaine is a naturally occurring alkaloid found in the iboga plant, used in West African Bwiti spiritual tradition and, since the 1960s, in underground Western treatment protocols primarily targeting opioid use disorder. Its legal status in the United States is simple to state and more complicated in practice.

Federal status: Schedule I

Ibogaine has been Schedule I of the Controlled Substances Act since 1970. Schedule I means the DEA has judged it to have no accepted medical use and a high potential for abuse - the same classification as heroin, LSD and psilocybin. Possession, manufacture, and distribution outside of DEA-registered research contexts are federal crimes.

What the April 2026 executive order does (and does not do)

The executive order signed April 18, 2026 directs the FDA and DEA to establish a pathway for eligible patients to access investigational psychedelic drugs, *including ibogaine compounds*, under the federal Right to Try Act. It does not legalize ibogaine, does not reschedule it, and does not allow any form of recreational or retail access.

What it does do is set up an access route for patients who meet specific criteria - typically a life-threatening diagnosis, exhausted conventional options, and enrollment tied to an active FDA-reviewed clinical program. The rule-making that defines who qualifies and how access works has not yet been published. Expect 60 to 120 days.

State-level picture

No US state has legalized ibogaine for personal possession or clinical use. A handful of states have pursued state-level ibogaine research or funding conversations: Kentucky's opioid abatement trust, Ohio's ibogaine pilot program discussions, and Texas (with a 2023 state research grant program). Those are research tracks, not patient access.

Clinical trials on US soil

Several ibogaine and noribogaine (a longer-acting metabolite) programs are in various stages with the FDA. DemeRx runs an ibogaine program for opioid use disorder. Atai Life Sciences' noribogaine arm is in Phase 1 safety work. Stanford and NYU both run ibogaine-adjacent research. You can search current programs on ClinicalTrials.gov by the term *ibogaine* - this is the cleanest and most legal path for a US resident to access ibogaine in 2026.

International treatment centers

Ibogaine is legal (or unscheduled, which is different from legal but practically the same) in Mexico, Costa Rica, New Zealand, parts of Canada (Kelowna, BC has had operating centers since the early 2010s), and several European countries including Portugal and the Netherlands.

Mexico is the most common destination for US veterans specifically. Centers like Crossroads, Beond, and Ambio operate with medical screening, cardiac monitoring, and integration protocols. Cost runs $6,000-$15,000+ for a 5-7 day program. Mexico is not a regulatory vacuum - most credible centers operate under a specific Mexican health permit and coordinate with US-licensed prescribers for pre-screening.

Medical screening is not optional

Ibogaine carries real cardiac risk. QTc prolongation during the dose window is well documented, and there have been deaths linked to undisclosed cardiac conditions, drug interactions, or inadequate monitoring. Any program - US trial, Mexican clinic, anywhere - should require a baseline ECG, liver panel, full medication review, and continuous cardiac monitoring during dosing. If a program does not require those, walk away.

What to expect from the Right to Try rule

The executive order is a directive to the agencies; the binding access criteria will come out of FDA and DEA rule-making. The pattern from prior Right to Try implementations suggests: eligibility tied to a specific diagnosis and failed-conventional-treatment requirement, an active drug sponsor willing to provide the investigational compound, a physician supervisor, informed consent, and FDA reporting. It is not likely to be a broad consumer-access mechanism.

Our directory position

LicensedPsychedelics does not list providers operating outside the legal framework in their jurisdiction. Until the Right to Try pathway produces an actual US program with FDA-registered sponsors and DEA-approved sites, our ibogaine section points to FDA clinical trials and to internationally licensed centers with verified medical protocols. When the first US Right to Try site opens, we will verify and list it against the issuing authority - the same way we handle every other modality on this site.

Sources

The White House fact sheet on the 2026 executive order. DEA Schedule I list (21 CFR 1308.11). 21st Century Cures Act and Right to Try Act. MAPS and Heroic Hearts Project public testimony on veteran ibogaine access. Noller GE et al., 'Ibogaine treatment outcomes' (American Journal of Drug and Alcohol Abuse, 2018).